Cost-Effectiveness of Liposomal vs Conventional Cytarabine-Daunorubicin for AML

In a study comparing the cost-effectiveness of liposomal cytarabine-daunorubicin (CPX-351) with conventional cytarabine-daunorubicin in the treatment of acute myeloid leukemia (AML), Jan Bewersdorf, MD, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, and colleagues found that CPX-351 may not be cost-effective under the current pricing.